Pharming Group reports second quarter and first half 2023 financial results
Financial updatesPharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.
Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.
Pharming Group N.V. announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.
Pharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.
Pharming is delighted to announce that CEO Sijmen de Vries was the winner of the Chief Executive of the Year Award at the 2023 European Mediscience Awards in London on Thursday evening. Scroll down for the Dutch translation.
Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.
Pharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June:
Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.
Pharming Group N.V. presents its preliminary, unaudited financial report for the first quarter ended March 31, 2023.
Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.
Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries and Chief Financial Officer, Jeroen Wakkerman will attend the Van Lanschot Kempen Life Sciences Conference on April 25 and 26, 2023 in Amsterdam, the Netherlands.
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.